Research programme: angiostatin proteins - Bolder BioTechnology
Alternative Names: Angiostatin - Bolder BioTechnologyLatest Information Update: 07 Mar 2011
At a glance
- Originator Bolder BioTechnology
- Class Proteins
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Rheumatoid arthritis
Most Recent Events
- 01 Aug 2007 Early research is ongoing in the US
- 20 Jan 2005 Early research in Rheumatoid arthritis in USA (unspecified route)
- 27 Nov 2002 Early research in Cancer in USA (unspecified route)